Therapeutic strategies in adrenoleukodystrophy
Autor: | Ann B. Moser, Ali Fatemi, Bela R. Turk |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty medicine.medical_treatment DNA Mutational Analysis Hematopoietic stem cell transplantation 03 medical and health sciences Neonatal Screening 0302 clinical medicine Internal medicine medicine Humans Adrenoleukodystrophy Child Brain Diseases Chromosomes Human X Cell Death business.industry Hematopoietic Stem Cell Transplantation Infant Newborn General Medicine 030104 developmental biology Disease Progression business 030217 neurology & neurosurgery Demyelinating Diseases |
Zdroj: | Wiener Medizinische Wochenschrift. 167:219-226 |
ISSN: | 1563-258X 0043-5341 |
DOI: | 10.1007/s10354-016-0534-2 |
Popis: | Adrenoleukodystrophy (ALD) is an X‑linked hereditary disorder due to mutations of the ABCD1 gene, which encodes a peroxisomal transport protein necessary for very long-chain fatty acid degradation (VLCFA). Toxic accumulation thereof is associated with a proinflammatory state and eventual cell death in multiple tissues. ALD may manifest either as a fatal, rapidly progressive demyelinating disease in boys and adult men, or as a slowly progressive adult-onset long-tract myelopathy along with peripheral neuropathy. Our understanding of manifold mechanisms implicated in the disease pathology is currently incomplete, as neither genotype-phenotype correlation nor the trigger for cerebral disease has been described. Therapy objectives are therefore broadly aimed at correcting either the gene mutation or downstream molecular effects, such as oxidative stress. Advancements in disease detection, including the newly implemented newborn screening in the US and imaging modalities, allow for more timely intervention in the form of hematopoietic stem cell transplantation (HSCT), which may only be performed in early cerebral disease states. |
Databáze: | OpenAIRE |
Externí odkaz: |